Table 3. Prognostic factors in 490 NPC patients identified using univariate analysis.
| Characteristic | N | LRRFS (%) | p | DMFS (%) | p | PFS (%) | p | OS (%) | p |
|---|---|---|---|---|---|---|---|---|---|
| Age | 0.050 | 0.340 | 0.761 | 0.003 | |||||
| < 50 | 280 | 96.8 | 93.3 | 90.5 | 95.3 | ||||
| ≥ 50 | 210 | 95.1 | 86.2 | 91.8 | 87.5 | ||||
| Gender | 0.517 | 0.028 | 0.175 | 0.360 | |||||
| Male | 94 | 96.4 | 93.0 | 89.7 | 91.3 | ||||
| Female | 38 | 95.2 | 98.0 | 93.9 | 93.7 | ||||
| T stage | 0.306 | 0.820 | 0.497 | 0.867 | |||||
| T1-2 | 82 | 94.6 | 95.1 | 89.9 | 92.3 | ||||
| T3-4 | 408 | 96.3 | 94.3 | 91.2 | 92.0 | ||||
| N stage | 0.788 | 0.211 | 0.373 | 0.136 | |||||
| N0-1 | 142 | 96.4 | 96.4 | 92.9 | 94.5 | ||||
| N2-3 | 348 | 95.9 | 93.7 | 90.2 | 91.0 | ||||
| Clinical stage | 0.370 | 0.166 | 0.073 | <0.001 | |||||
| III | 279 | 96.6 | 96.1 | 93.1 | 96.2 | ||||
| IVA/B | 211 | 95.2 | 92.3 | 88.2 | 86.6 | ||||
| IC cycle | 0.302 | 0.120 | 0.520 | 0.811 | |||||
| 2 | 270 | 95.3 | 95.9 | 92.0 | 91.3 | ||||
| 3-4 | 220 | 96.8 | 92.7 | 89.6 | 93.0 | ||||
| IC regimen | 0.199 | 0.554 | 0.835 | 0.434 | |||||
| TPF | 57 | 96.4 | 87.7 | 86.0 | 94.7 | ||||
| TP | 75 | 90.3 | 91.9 | 85.2 | 92.0 | ||||
| AC | 0.101 | 0.767 | 0.255 | 0.552 | |||||
| No | 267 | 97.4 | 94.8 | 92.3 | 93.0 | ||||
| Yes | 223 | 94.5 | 94.1 | 89.6 | 90.8 |
Abbreviations: LRRFS, locoregional relapse-free survival; DMFS, distant metastases-free survival; PFS, progression-free survival; OS, overall survival; IC, induction chemotherapy; TP, docetaxel/cisplatin; TPF, docetaxel/cisplatin/fluorouracil.